Results 241 to 250 of about 80,706 (309)

Purdue's development of abuse-deterrent formulation opioids as a response to market competition: An industry documents analysis. [PDF]

SSM Qual Res Health
DiMario A, Knight K, Schmidt LA, Apollonio DE.   +3 more
europepmc   +1 more source

Trends in the utilization, expenditure and costs of noninsulin glucose‐lowering drugs in the Medicaid population: Steady increases in glucagon‐like peptide‐1 receptor agonist and sodium–glucose transporter‐2 inhibitor use, prices and expenditure

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to analyse changes in the utilization, expenditure and average cost of noninsulin glucose‐lowering drugs (GLDs) between 2008 and 2023. Methods This was a retrospective observational study of 2008–2023 data from the National Medicaid State Drug Utilization database.
Rawan O. Almadfaa
wiley   +1 more source

A primer on prescription drug pricing benchmarks in the United States. [PDF]

J Manag Care Spec Pharm
Hung A, Dickson S.
europepmc   +1 more source

Trends in 25 years of antihypertensive agent utilization in Croatia – an alert for scientific community and healthcare providers

British Journal of Clinical Pharmacology, EarlyView.
Aims Hypertension is a leading modifiable risk factor for cardiovascular mortality worldwide. This study aimed to evaluate 25‐year trends in antihypertensive agent (AHA) utilization in Croatia between 2000 and 2024. Methods We conducted a national, population‐based analysis using IMS and IQVIA pharmaceutical databases.
Andrej Belančić, Marta Kučan Štiglić, Ana Jelaković, Bojan Jelaković, Dinko Vitezić   +4 more
wiley   +1 more source

Medicare Part D Formulary Coverage of Disease-Modifying Therapies for Multiple Sclerosis.

JAMA Health Forum
Li P, Klebanoff MJ, Lin JK, Doshi KD, Chahin S, Doshi JA.   +5 more
europepmc   +1 more source

Potential impact of tariffs on active pharmaceutical ingredients on the price of US-made generic drugs. [PDF]

Health Aff Sch
Socal MP, Sun Y, Ballreich J, Acha J, Yazdi MA, Dai T, Dada M.   +6 more
europepmc   +1 more source

Early‐stage health technology assessment of a curative gene therapy for multiple sclerosis

British Journal of Clinical Pharmacology, EarlyView.
Aims Multiple sclerosis (MS) is associated with significant early morbidity, reduced life expectancy and substantial healthcare and societal costs. The primary objective of this study is to assess the early cost‐effectiveness potential of a novel gene therapy, IMMUTOL, for MS compared with current high‐efficacy treatment sequences.
Attila Imre, Balázs Nagy, Rok Hren
wiley   +1 more source

Availability and Cost of Naloxone Over Time: A Longitudinal Secret Shopper Study in North Carolina Community Pharmacies. [PDF]

J Am Pharm Assoc (2003)
Johnson JM, Marley GT, Annis IE, Carpenter DM.   +3 more
europepmc   +1 more source

Post-market surveillance of albendazole tablet brands in Kenya: Implications for deworming programs and clinical outcomes. [PDF]

PLoS Negl Trop Dis
Yator EK, Njogu PM.
europepmc   +1 more source

Generic Prescribing and Generic Drugs in Proper Medical Services. Generic Drugs in National Hospitals: The Situation of Using Generic Drugs.

Japanese Journal of National Medical Services, 2002
openaire   +1 more source